close

Insmed Incorporated, a development stage company, engages in the development of recombinant protein drug. The company's primary product includes IPLEX, a complex of recombinant human IGF-1 and its binding protein IGFBP-3 for use in the treatment of several serious medical conditions, as well as conducting a phase III enabling clinical trial for investigating IPLEX as a treatment for myotonic muscular dystrophy. Insmed also engages in various oncology programs, including INSM-18, an orally available small molecule tyrosine kinase inhibitor that has demonstrated selective inhibition of IGF-1 and human epidermal growth factor receptor; and rhIGFBP-3, which is in early clinical development stage for the treatment of breast, prostate, liver, ovarian, and colon cancers. The company also provides Expanded Access Program in Italy to offer IPLEX to physicians for use in their patients with amyotrophic lateral sclerosis. It has a license to Pharmacia AB's portfolio of regulatory filings pertaining to rhIGF; and an agreement with NAPO Pharmaceuticals that gives NAPO the right to develop, manufacture, and commercialize masoprocal products for various indications relating to diabetes, cardiac disease, vascular disease, metabolic disease, and syndrome X. The company was founded in 1999 and is headquartered in Richmond, Virginia.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	3.93
Volume	114777
Volume Avg	146210
52 Week High	13.50
52 Week Low	2.64
PE	N/A
PE (group average)	39
EPS Year	-2.78
EPS change Q/Q	-102.38%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	-102.38%
EPS change Y/Y	-1000%
REV change Q/Q	23.08%
REV change Q/Q Yr ago	-15.79%
EPS next Q est	-0.42
EPS next Y est	-1.64
Divident Annual	0.00
Dividend Yield	0%